Evidence map›Paper›PMID 39379183›Full record

ArticleJournal of pediatric surgery2025

A Comparison of in vivo Tumor-Homing Abilities of Placental-Derived and Bone Marrow-Derived Mesenchymal Stromal Cells in High-Risk Neuroblastoma.

Kathleen Doyle, Abd-Elrahman Hassan, Maria Sutter, Monica Rodriguez, Priyadarsini Kumar, Erin Brown

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pediatric surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kathleen DoyleDepartment of Surgery, University of California-Davis, Sacramento, CA, USA. Electronic address: kedoyle@ucdavis.edu.
Abd-Elrahman HassanDepartment of Surgery, University of California-Davis, Sacramento, CA, USA.
Maria SutterSurgical Bioengineering Laboratory, Department of Surgery, University of California-Davis, Sacramento, CA, USA.
Monica RodriguezSurgical Bioengineering Laboratory, Department of Surgery, University of California-Davis, Sacramento, CA, USA.
Priyadarsini KumarSurgical Bioengineering Laboratory, Department of Surgery, University of California-Davis, Sacramento, CA, USA.
Erin BrownDepartment of Surgery, Division of Pediatric Surgery, University of California-Davis, Sacramento, CA, USA.

Funding

UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development ProgramK12CA138464 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BIRKELAND, ANDREW CHARLES, LARA, PRIMO N. · 2011 to 2025
$11.4M
UC Davis Comparative Oncology Training ProgramT32CA251007 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Robert J. Canter, Xinbin Chen · 2020 to 2026
$1.8M
NCI NIH HHS K12 CA138464NCI NIH HHS T32 CA251007
6 · The paper itself

Abstract

backgroundNeuroblastoma is a highly lethal malignancy of young children. Mesenchymal stromal cells (MSCs) may represent a novel cellular delivery vehicle due to their innate tumor-homing properties. We compared in vivo homing abilities of placental-derived MSCs (PMSCs) and bone marrow-derived MSCs (BM-MSCs) in an orthotopic neuroblastoma xenograft.

methods28 mice underwent direct implantation of neuroblastoma cells (cell line NB1643) into the adrenal gland followed by intraperitoneal injection of 5 × 10

resultsIVIS demonstrated initial diffuse signal that migrated to the left abdomen. Radiance decreased over time, but MSC signal persisted at day 7 in all animals. Ex vivo IVIS demonstrated signal in the adrenal tumor but not other organs. There was no significant difference in average ex vivo adrenal mass radiance between MSC groups (p = 0.74). IHC confirmed presence of both MSC types within the tumor.

conclusionPMSCs and BM-MSCs successfully migrated to neuroblastoma tumor tissues in vivo without evidence of migration to other organs. MSCs migrate within 72 h and persisted within the tumor up to 7 days. There was no significant difference in homing capabilities of PMSCs compared to BM-MSCs, indicating that either cell type has potential as a drug delivery vehicle. TYPE OF STUDY: Original Research. LEVEL OF EVIDENCE: n/a.

Indexed as

Adrenal Gland NeoplasmsBone Marrow CellsMesenchymal Stem CellsMesenchymal Stem Cell TransplantationNeuroblastomaPlacentaAnimalsCell Line, TumorCell MovementFemaleHumansMicePregnancyMesenchymal stromal cellNeuroblastomaPediatric oncologyPlacental-derived mesenchymal stromal cellTumor-homing

Identifiers

PMID39379183
PMCPMC12068278

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.